Annual FCF
-$595.51 M
-$80.24 M-15.57%
31 December 2023
Summary:
Apellis Pharmaceuticals annual free cash flow is currently -$595.51 million, with the most recent change of -$80.24 million (-15.57%) on 31 December 2023. During the last 3 years, it has fallen by -$429.60 million (-258.93%). APLS annual FCF is now -17187.66% below its all-time high of -$3.44 million, reached on 31 December 2013.APLS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$34.10 M
+$42.52 M+504.51%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly free cash flow is currently $34.10 million, with the most recent change of +$42.52 million (+504.51%) on 30 September 2024. Over the past year, it has increased by +$203.23 million (+120.16%). APLS quarterly FCF is now -75.86% below its all-time high of $141.27 million, reached on 31 December 2020.APLS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$205.58 M
+$203.23 M+49.71%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM free cash flow is currently -$205.58 million, with the most recent change of +$203.23 million (+49.71%) on 30 September 2024. Over the past year, it has increased by +$433.55 million (+67.83%). APLS TTM FCF is now -2339.53% below its all-time high of -$8.43 million, reached on 31 March 2017.APLS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.6% | +120.2% | +67.8% |
| 3 y3 years | -258.9% | +120.2% | +33.8% |
| 5 y5 years | -353.8% | +163.1% | -17.4% |
APLS Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -258.9% | at low | at high | +119.2% | at high | +67.8% |
| 5 y | 5 years | -353.8% | at low | -75.9% | +119.2% | -23.9% | +67.8% |
| alltime | all time | <-9999.0% | at low | -75.9% | +119.2% | -2339.5% | +67.8% |
Apellis Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $34.10 M(-504.5%) | -$205.58 M(-49.7%) |
| June 2024 | - | -$8.43 M(-93.7%) | -$408.81 M(-25.8%) |
| Mar 2024 | - | -$133.28 M(+36.0%) | -$550.90 M(-7.5%) |
| Dec 2023 | -$595.51 M(+15.6%) | -$97.97 M(-42.1%) | -$595.51 M(-6.8%) |
| Sept 2023 | - | -$169.13 M(+12.4%) | -$639.13 M(+2.3%) |
| June 2023 | - | -$150.53 M(-15.4%) | -$624.61 M(+7.4%) |
| Mar 2023 | - | -$177.88 M(+25.6%) | -$581.50 M(+12.9%) |
| Dec 2022 | -$515.27 M(-8.7%) | -$141.59 M(-8.4%) | -$515.27 M(+6.0%) |
| Sept 2022 | - | -$154.61 M(+43.9%) | -$486.19 M(-2.9%) |
| June 2022 | - | -$107.42 M(-3.8%) | -$500.56 M(-4.1%) |
| Mar 2022 | - | -$111.65 M(-0.8%) | -$522.08 M(-7.5%) |
| Dec 2021 | -$564.23 M(+240.1%) | -$112.52 M(-33.4%) | -$564.23 M(+81.7%) |
| Sept 2021 | - | -$168.98 M(+31.1%) | -$310.44 M(+26.7%) |
| June 2021 | - | -$128.94 M(-16.2%) | -$245.03 M(+16.2%) |
| Mar 2021 | - | -$153.80 M(-208.9%) | -$210.92 M(+27.1%) |
| Dec 2020 | -$165.91 M | $141.27 M(-236.4%) | -$165.91 M(-57.4%) |
| Sept 2020 | - | -$103.56 M(+9.2%) | -$389.40 M(+14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$94.83 M(-12.8%) | -$339.91 M(+19.2%) |
| Mar 2020 | - | -$108.78 M(+32.3%) | -$285.18 M(+34.0%) |
| Dec 2019 | -$212.83 M(+62.2%) | -$82.23 M(+52.1%) | -$212.83 M(+21.6%) |
| Sept 2019 | - | -$54.07 M(+34.8%) | -$175.08 M(+13.6%) |
| June 2019 | - | -$40.10 M(+10.1%) | -$154.14 M(+6.5%) |
| Mar 2019 | - | -$36.44 M(-18.1%) | -$144.74 M(+10.3%) |
| Dec 2018 | -$131.24 M(+181.7%) | -$44.48 M(+34.2%) | -$131.24 M(+28.3%) |
| Sept 2018 | - | -$33.13 M(+7.9%) | -$102.30 M(+27.4%) |
| June 2018 | - | -$30.69 M(+33.8%) | -$80.30 M(+31.4%) |
| Mar 2018 | - | -$22.94 M(+47.7%) | -$61.10 M(+31.1%) |
| Dec 2017 | -$46.60 M(+79.2%) | -$15.53 M(+39.5%) | -$46.60 M(+50.0%) |
| Sept 2017 | - | -$11.14 M(-3.1%) | -$31.06 M(+55.9%) |
| June 2017 | - | -$11.50 M(+36.4%) | -$19.92 M(+136.4%) |
| Mar 2017 | - | -$8.43 M | -$8.43 M |
| Dec 2016 | -$26.00 M(+37.9%) | - | - |
| Dec 2015 | -$18.86 M(+89.2%) | - | - |
| Dec 2014 | -$9.97 M(+189.3%) | - | - |
| Dec 2013 | -$3.44 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual FCF year-on-year change?
- What is Apellis Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly FCF year-on-year change?
- What is Apellis Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM FCF year-on-year change?
What is Apellis Pharmaceuticals annual free cash flow?
The current annual FCF of APLS is -$595.51 M
What is the all time high annual FCF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual free cash flow is -$3.44 M
What is Apellis Pharmaceuticals annual FCF year-on-year change?
Over the past year, APLS annual free cash flow has changed by -$80.24 M (-15.57%)
What is Apellis Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of APLS is $34.10 M
What is the all time high quarterly FCF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly free cash flow is $141.27 M
What is Apellis Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, APLS quarterly free cash flow has changed by +$203.23 M (+120.16%)
What is Apellis Pharmaceuticals TTM free cash flow?
The current TTM FCF of APLS is -$205.58 M
What is the all time high TTM FCF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM free cash flow is -$8.43 M
What is Apellis Pharmaceuticals TTM FCF year-on-year change?
Over the past year, APLS TTM free cash flow has changed by +$433.55 M (+67.83%)